Literature DB >> 25436810

First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?

Marcello Tiseo1, Andrea Ardizzoni, Luca Boni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25436810     DOI： 10.1097/JTO.0000000000000272

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.

Authors:  Vitor F Vasconcellos; Guilherme N Marta; Edina Mk da Silva; Aecio Ft Gois; Tiago B de Castria; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

2.  Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.

Authors:  George Mattheolabakis; Dandan Ling; Gulzar Ahmad; Mansoor Amiji
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

3.  Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.

Authors:  Min-Che Tung; Po-Lin Lin; Yao-Chen Wang; Tsung-Ying He; Ming-Ching Lee; Sauh D Yeh; Chih-Yi Chen; Huei Lee
Journal:  Oncotarget       Date:  2015-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.